Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study

Major Depressive Disorder Clinical Trial

Official title:

Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03523767
• Other study ID #: HSC-MS-16-0496
• Status: Terminated
• Phase: Phase 1
• Start date: February 7, 2018
• Est. completion date: February 7, 2020

Study information

• Verified date: March 2023
• Source: The University of Texas Health Science Center, Houston
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this pilot study is to investigate and compare the effect of a mild inflammatory stimulus (typhoid vaccine) on immune response, mood and cognition in healthy volunteers compared to patients with history Major Depressive Disorder (MDD) (not currently depressed and no symptoms of depression in the past 6 months).

Description:

Study design: In this double blind randomized crossover design, each participant will receive saline injection or typhoid vaccine injection at the first study visit, and will then receive the other injection at the second study visit. All participants will undergo study procedures (clinical and imaging) in two separate sessions after each injection given at least 7 days apart (within 10-14 days). Baseline blood samples will be taken and vital signs will be measured. Participants will be asked to complete the mood questionnaires and computerized reward tasks. Then, injections of normal saline will be administered intramuscularly in the deltoid muscle. At 1.5h, 3h, 4h and 6h after the injection, the subjects will complete the mood questionnaires and vital signs will be assessed. The computer based task will be repeated at 3h. Between3h and 6h after the injection blood samples will be collected for cytokines measurement. At 4h, a structural magnetic resonance imaging (MRI), and Functional magnetic resonance imaging (fMRI) will be done. Follow up visits/calls with the patients will be set to check their physical and mood status.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 19
• Est. completion date: February 7, 2020
• Est. primary completion date: February 7, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers, male or female; aged 18-65
• Subjects with history of Major depression (currently asymptomatic - symptom free for more than 6 months)
• Medication free, if not feasible being on antidepressants will be allowed

Exclusion Criteria:

• Volunteers who received this vaccine within 3 years or any other vaccine within 3 months
• Patients with existing inflammatory conditions (connective tissue disorder, autoimmune conditions, neoplastic disease, chronic infections, etc.)
• Patients with acute viral or bacterial infection
• Hospitalized patients
• Patients in acute phase of illness
• Current active medical condition that affect brain anatomy, neurochemistry, or function, e.g. liver insufficiency, kidney insufficiency, cardiovascular problems, systemic infections, cancer, hypothyroidism, auto-immune diseases, and any brain disorder (seizure disorder, stroke, dementia, degenerative neurologic diseases)
• History of any brain diseases, including seizures, stroke, meningitis, encephalitis, dementia, degenerative brain diseases, and serious head injury with loss of consciousness
• Family history of hereditary neurologic disorder
• Floating metallic objects in the body
• Pregnancy
• Exposure to regular use of anti-inflammatory drugs in the last one month
• Excessive exercise, consumption of caffeinated beverages or alcohol, high-fat meals 12 hours before testing
• History of tobacco, alcohol, or drug abuse or dependence.
• History of allergic reaction to vaccination or serious allergic reaction to shellfish or egg allergy

Related Conditions & MeSH terms

• Depressive Disorder
• Depressive Disorder, Major
• Inflammation
• Major Depressive Disorder
• Mood Disorders

Intervention

Biological:
• S.typhi Injection
0.5 ml of S.typhi injection
• Normal Saline Injection
0.5 ml of normal saline injection

Locations

Country	Name	City	State
United States	Sudhakar Selvaraj	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Inflammation as indicated by cytokines	To compare proinflammatory cytokines (e.g. IL-6, TNF-a, etc) concentration between the experimental (receiving S.typhi vaccine) and the control group (receiving normal saline).	baseline, 3-6 hours post-injection
Primary	Change in depressed mood as indicated by Hamilton Depression Rating Scale (HAM-D) score	To compare the severity of mood symptoms (as scored on the Hamilton Depression Rating Scale) between the experimental and the control group. A score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates at least moderate severity of depressive symptoms. Scores range from 0-53.	baseline, 3-6 hours post-injection
Primary	Level of prefrontal, limbic and striatal cortex activation as indicated by fMRI	Compare prefrontal cortex response to reward anticipation between the experimental and the control group, using fMRI	3-6 hours post-injection